Losartan Pharmacokinetics (ADME): Absorption, Metabolism, and Clinical Implications

How Losartan Works: Mechanism of Action at the AT1 Receptor

Losartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from triggering vasoconstriction, aldosterone secretion, and sympathetic activation. This competitive antagonism lowers blood pressure without suppressing the ACE-mediated bradykinin pathway, which is why ARBs cause cough far less often than ACE inhibitors [1].

The distinction between losartan and its metabolite matters at the receptor level. Losartan itself is a competitive, surmountable antagonist: high concentrations of angiotensin II can partially overcome its blockade. EXP3174, by contrast, binds the AT1 receptor in an insurmountable (pseudo-irreversible) fashion, meaning its inhibition persists even when angiotensin II concentrations rise [2]. This pharmacodynamic difference explains why the metabolite drives most of losartan's sustained antihypertensive effect across a 24-hour dosing interval.

The AT1 receptor mediates nearly all of angiotensin II's known cardiovascular and renal effects. By blocking AT1 while leaving the AT2 receptor unoccupied, losartan may allow angiotensin II to stimulate AT2-mediated pathways associated with vasodilation, antiproliferation, and tissue repair [3]. Whether this AT2 "escape" confers meaningful clinical benefit beyond blood pressure reduction remains under investigation, though the LIFE trial (N=9,193) demonstrated a 13% reduction in the composite primary endpoint of cardiovascular death, stroke, and myocardial infarction versus atenolol, despite similar blood pressure reductions in both arms [4]. That finding suggested receptor-level effects beyond simple hemodynamic control.

Absorption: Oral Uptake and First-Pass Losses

Losartan is well absorbed from the gastrointestinal tract after oral administration, but systemic bioavailability reaches only about 33% because of substantial first-pass hepatic extraction [1]. Peak plasma concentrations of the parent compound appear within approximately 1 hour of dosing.

Food slows absorption modestly but does not reduce the total amount absorbed (AUC), so losartan can be taken with or without meals [1]. The FDA-approved prescribing information notes that "the pharmacokinetics of losartan and its active metabolite are linear with oral losartan potassium doses up to 200 mg" [1]. This linearity simplifies dose adjustments: doubling the dose roughly doubles plasma exposure across the approved range of 25 to 100 mg daily.

Losartan undergoes extensive presystemic metabolism. The drug is a substrate for cytochrome P450 enzymes in the liver and intestinal wall before reaching systemic circulation, and roughly 14% of the administered dose is converted to EXP3174 during this first pass [5]. The remaining parent compound that does enter the bloodstream circulates with high protein binding (98.7%, primarily to albumin) and a volume of distribution of approximately 34 liters [1].

One practical consequence of this pharmacokinetic profile: patients with significant hepatic impairment show plasma concentrations of losartan and EXP3174 that are approximately 5-fold and 1.7-fold higher, respectively, than in healthy volunteers [1]. The prescribing information recommends a starting dose of 25 mg in patients with hepatic impairment for this reason.

Distribution: Protein Binding, Volume of Distribution, and Tissue Penetration

Losartan distributes into a relatively confined volume (approximately 34 L), suggesting it remains largely in the vascular and extracellular fluid compartments rather than partitioning extensively into deep tissue stores [1]. Both losartan and EXP3174 bind tightly to plasma proteins. Losartan binds at 98.7% and EXP3174 at 99.8%, almost exclusively to albumin [1].

The clinical implication of this binding pattern: displacement interactions are theoretically possible but have not proven clinically significant in practice. Neither compound displaces warfarin, digoxin, or phenytoin from albumin binding sites at therapeutic concentrations [1]. However, in patients with severe hypoalbuminemia (nephrotic syndrome, cirrhosis, or critical illness), unbound fractions could increase, potentially amplifying the drug's effect.

Losartan does not readily cross the blood-brain barrier. Animal data show brain-to-plasma ratios well below unity, which aligns with clinical observations that central nervous system side effects are uncommon with ARBs [6]. The drug does cross the placenta, which is the basis for the FDA's boxed warning against use during the second and third trimesters of pregnancy due to fetal renal toxicity and death [1].

Regarding breast milk, no human data exist for losartan, but given its high molecular weight and extensive protein binding, excretion into milk is expected to be low. The prescribing information nonetheless advises against use during breastfeeding [1].

Metabolism: CYP2C9, EXP3174, and the Prodrug Question

Losartan's metabolic pathway is central to its clinical pharmacology. The parent drug undergoes oxidation primarily by CYP2C9, with a smaller contribution from CYP3A4, to produce the active carboxylic acid metabolite E-3174 (commonly called EXP3174) [5]. This metabolite accounts for about 14% of an oral dose but is responsible for most of the sustained AT1 receptor blockade.

Whether losartan qualifies as a "prodrug" has been debated. Strictly, it is not: losartan itself has intrinsic pharmacologic activity at the AT1 receptor. But its metabolite is so much more potent (10 to 40 times by receptor binding assays) and has a longer half-life (6 to 9 hours versus approximately 2 hours) that the metabolite dominates the therapeutic effect [2]. Dr. Ronald D. Smith, one of the Merck pharmacologists involved in losartan's development, described EXP3174 as "the principal contributor to AT1 receptor blockade during chronic therapy" [7].

CYP2C9 Polymorphisms and Poor Metabolizers

The CYP2C9 gene is polymorphic. Carriers of loss-of-function alleles (CYP2C9*2 and CYP2C9*3) convert less losartan to EXP3174, resulting in higher parent drug levels and lower active metabolite exposure [8]. In CYP2C9 poor metabolizers (homozygous *3/*3, representing roughly 1 to 3% of Caucasian populations), EXP3174 formation is reduced by approximately 75% compared to extensive metabolizers [8].

The Clinical Pharmacogenetics Implementation Consortium (CPIC) does not currently publish specific dosing guidelines for losartan based on CYP2C9 genotype, but the Dutch Pharmacogenetics Working Group (DPWG) recommends considering an alternative ARB (such as valsartan or candesartan, which do not depend on CYP2C9 for activation) in confirmed CYP2C9 poor metabolizers who show inadequate blood pressure response [9]. A 2014 pharmacogenomic analysis published in Clinical Pharmacology & Therapeutics found that CYP2C9*3 carriers had a 4.2 mmHg smaller reduction in systolic blood pressure compared to wild-type patients receiving the same losartan dose [10].

Drug Interactions Affecting CYP2C9

Potent CYP2C9 inhibitors can mimic the poor-metabolizer phenotype pharmacologically. Fluconazole, a strong CYP2C9 inhibitor, increased losartan AUC by 69% and decreased EXP3174 AUC by 41% in a crossover study of healthy volunteers [11]. Other CYP2C9 inhibitors of clinical relevance include amiodarone, fluvoxamine, and sulfamethoxazole.

CYP2C9 inducers (rifampin being the most potent clinically used example) have the opposite effect, accelerating losartan clearance and potentially reducing both parent drug and metabolite exposure. Rifampin co-administration reduced losartan AUC by approximately 35% and EXP3174 AUC by approximately 40% in published interaction studies [12]. Clinicians should monitor blood pressure closely when initiating or discontinuing strong CYP2C9 modulators in patients on losartan.

Elimination: Renal and Biliary Clearance Pathways

Losartan and its metabolites are eliminated through dual pathways. Approximately 35% of a dose is recovered in urine and about 60% in feces, the fecal fraction reflecting biliary excretion of both parent compound and metabolites [1].

Renal clearance of losartan is about 75 mL/min, and for EXP3174, about 25 mL/min, indicating that the metabolite is cleared more slowly [1]. Total plasma clearance of losartan is roughly 600 mL/min, consistent with significant hepatic extraction. The terminal half-life of losartan is approximately 2 hours. EXP3174 has a terminal half-life of 6 to 9 hours [1].

Renal Impairment

In patients with creatinine clearance above 30 mL/min, no dose adjustment is needed. Losartan and EXP3174 pharmacokinetics are not significantly altered in mild-to-moderate renal impairment [1]. In hemodialysis patients, losartan and EXP3174 are not removed by dialysis due to their extensive protein binding [1]. This means a missed dose cannot be "caught up" with a post-dialysis supplemental dose. The prescribing information does not require dose reduction for renal impairment alone, though monitoring of serum potassium is advised because ARBs can exacerbate hyperkalemia in patients with reduced GFR.

Hepatic Impairment

Hepatic impairment has a more pronounced effect on losartan pharmacokinetics than renal impairment does. In patients with mild-to-moderate hepatic cirrhosis, losartan oral clearance decreased and plasma AUC values were approximately 5 times those seen in healthy volunteers [1]. The FDA label specifies a reduced starting dose of 25 mg for patients with a history of hepatic impairment. This recommendation reflects the liver's dominant role in both first-pass metabolism and biliary elimination of the drug.

Pharmacokinetic Comparison: Losartan Versus Other ARBs

Losartan's reliance on CYP2C9-mediated bioactivation distinguishes it from most other ARBs. Valsartan, for instance, has only about 20% hepatic metabolism and no active metabolite [13]. Candesartan is administered as the prodrug candesartan cilexetil, which is hydrolyzed during absorption to the active form without cytochrome P450 involvement [14]. Telmisartan undergoes glucuronidation rather than oxidative metabolism [15].

These differences carry practical implications. The Endocrine Society's 2017 clinical practice guideline on primary aldosteronism noted that ARBs can be used during confirmatory testing, with the caveat that "losartan's pharmacokinetic profile is more variable than that of other ARBs due to CYP2C9 polymorphism" [16]. For patients on multiple CYP2C9 substrates or known poor metabolizers, switching to an ARB with a more predictable metabolic pathway may simplify management.

One area where losartan's parent compound contributes a distinct pharmacologic effect is uric acid handling. Losartan (but not EXP3174, and not other ARBs) inhibits the URAT1 transporter in the proximal tubule, producing a mild uricosuric effect that reduces serum uric acid by approximately 0.5 to 1.0 mg/dL [17]. The LIFE trial investigators observed that about 29% of losartan's stroke-reduction benefit versus atenolol could be attributed to its uric acid-lowering effect in post hoc analysis [4]. Dr. Sverre Kjeldsen, a LIFE trial investigator, stated that "losartan's uricosuric property appears to offer an additional mechanism of cardiovascular protection beyond AT1 receptor blockade" [18].

Dosing Informed by Pharmacokinetics

Standard dosing of losartan for hypertension begins at 50 mg once daily, with titration to 100 mg once daily based on blood pressure response [1]. The 6-to-9-hour half-life of EXP3174 generally supports once-daily dosing, but some patients experience an end-of-dose blood pressure rise in the final 4 to 6 hours of the dosing interval.

Ambulatory blood pressure monitoring (ABPM) studies have reported trough-to-peak ratios for losartan 50 mg of approximately 50 to 60%, which is lower than the 60 to 80% range seen with longer-acting ARBs like telmisartan or olmesartan [19]. When 24-hour coverage is inadequate at 100 mg daily, splitting the dose to 50 mg twice daily can improve trough blood pressure control.

In patients with diabetic nephropathy (the indication studied in the RENAAL trial, N=1,513), losartan 50 to 100 mg daily reduced the risk of doubling of serum creatinine by 25% and end-stage renal disease by 28% compared to placebo, with benefits observed on top of conventional antihypertensive therapy [20]. The pharmacokinetic rationale for renal protection extends beyond blood pressure: sustained AT1 blockade reduces intraglomerular pressure by dilating the efferent arteriole, and the metabolite EXP3174's long receptor residence time may be more important for this effect than for systemic blood pressure lowering.

Losartan 25 mg should be the starting dose in three populations: patients with hepatic impairment, patients receiving high-dose diuretics (intravascular volume depletion risk), and patients over age 75 with heart failure [1].

Special Populations and Pharmacokinetic Considerations

Elderly Patients

In patients aged 65 and older, losartan and EXP3174 plasma concentrations are not significantly different from younger adults after correcting for renal function [1]. No age-based dose adjustment is required for hypertension. The LIFE trial enrolled patients aged 55 to 80 and demonstrated consistent benefit across age subgroups [4].

Pediatric Patients

Losartan is FDA-approved for hypertension in children aged 6 years and older. Pediatric pharmacokinetic data show similar absorption and metabolism patterns to adults, though weight-based dosing (0.7 mg/kg up to 50 mg daily) is recommended for children weighing 20 to 50 kg [1]. Limited data exist for children under age 6 or those weighing <20 kg.

Race and Ethnicity

The LIFE trial found that losartan's primary-endpoint benefit was attenuated in Black patients compared to the overall population, a finding consistent with the generally reduced antihypertensive response to renin-angiotensin system blockers observed in populations with lower baseline renin activity [4]. Pharmacokinetic parameters (AUC, Cmax, half-life) do not differ significantly by race, suggesting the reduced response is pharmacodynamic rather than pharmacokinetic in origin [1].